Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

1
results for

"Cardiomyopathy, cirrhosis"

Article category

Keywords

Publication year

"Cardiomyopathy, cirrhosis"

Original Article

Liver fibrosis, cirrhosis, and portal hypertension

Galectin-3 inhibits cardiac contractility via a tumor necrosis factor alpha-dependent mechanism in cirrhotic rats
Ki Tae Yoon, Hongqun Liu, Jing Zhang, Sojung Han, Samuel S. Lee
Clin Mol Hepatol 2022;28(2):232-241.
Published online January 5, 2022
DOI: https://doi.org/10.3350/cmh.2021.0141
Background/Aims
Galectin-3 plays a key pathogenic role in cardiac hypertrophy and heart failure. The present study aimed to investigate the effects of galectin-3 on cardiomyopathy – related factors and cardiac contractility in a rat model of cirrhotic cardiomyopathy.
Methods
Rats were divided into two sets, one for a functional study, the other for cardiac contractile-related protein evaluation. There were four groups in each set: sham operated and sham plus N-acetyllactosamine (N-Lac, a galectin-3 inhibitor; 5 mg/kg); bile duct ligated (BDL) and BDL plus N-Lac. Four weeks after surgery, ventricular level of galectin-3, collagen I and III ratio, tumor necrosis factor alpha (TNFα), and brain natriuretic peptide (BNP) were measured either by Western blots or immunohistochemistry or enzyme-linked immunosorbent assay. Blood pressure was measured by polygraph recorder. Cardiomyocyte contractility was measured by inverted microscopy.
Results
Galectin-3 and collagen I/III ratio were significantly increased in cirrhotic hearts. TNFα and BNP were significantly increased in BDL serum and heart compared with sham controls. Galectin-3 inhibitor significantly decreased galectin-3, TNFα, and BNP in cirrhotic hearts but not in sham controls. N-Lac also significantly improved the blood pressure, and systolic and diastolic cardiomyocyte contractility in cirrhotic rats but had no effect on sham controls.
Conclusion
Increased galectin-3 in the cirrhotic heart significantly inhibited contractility via TNFα. Inhibition of galectin-3 decreased the cardiac content of TNFα and BNP and reversed the decreased blood pressure and depressed contractility in the cirrhotic heart. Galectin-3 appears to play a pathogenic role in cirrhotic cardiomyopathy.

Citations

Citations to this article as recorded by  Crossref logo
  • Apoptosis in Cardiac Conditions Including Cirrhotic Cardiomyopathy
    Fengxue Yu, Dae Gon Ryu, Ki Tae Yoon, Hongqun Liu, Samuel S. Lee
    International Journal of Molecular Sciences.2025; 26(13): 6423.     CrossRef
  • Cirrhotic Cardiomyopathy: Bridging Hepatic and Cardiac Pathophysiology in the Modern Era
    Dragoș Lupu, Camelia Cornelia Scârneciu, Diana Țînț, Cristina Tudoran
    Journal of Clinical Medicine.2025; 14(17): 5993.     CrossRef
  • Galectin-3: A Multitasking Protein Linking Cardiovascular Diseases, Immune Disorders and Beyond
    Mariarosaria Morello, Gisella Titolo, Saverio D’Elia, Silvia Caiazza, Ettore Luisi, Achille Solimene, Chiara Serpico, Andrea Morello, Francesco Natale, Paolo Golino, Plinio Cirillo, Giovanni Cimmino
    Targets.2025; 3(4): 34.     CrossRef
  • Galectin-3 as a therapeutic target in pulmonary hypertension: Molecular mechanisms, drug development directions, and emerging clinical applications
    Antonín Sedlář, Pavla Bojarová, František Kolář, Vladimír Křen, Lucie Bačáková
    Biomedicine & Pharmacotherapy.2025; 193: 118756.     CrossRef
  • Cardiomyopathy in cirrhosis: From pathophysiology to clinical care
    Hongqun Liu, Jwan A. Naser, Grace Lin, Samuel S. Lee
    JHEP Reports.2024; 6(1): 100911.     CrossRef
  • Cirrhotic cardiomyopathy: Pathogenesis, clinical features, diagnosis, treatment and prognosis
    Francisca Almeida, Alexandra Sousa
    Revista Portuguesa de Cardiologia.2024; 43(4): 203.     CrossRef
  • Therapies for Cirrhotic Cardiomyopathy: Current Perspectives and Future Possibilities
    Hongqun Liu, Daegon Ryu, Sangyoun Hwang, Samuel S. Lee
    International Journal of Molecular Sciences.2024; 25(11): 5849.     CrossRef
  • Role of Galectin in Cardiovascular Conditions including Cirrhotic Cardiomyopathy
    Hongqun Liu, Sang-Youn Hwang, Samuel S. Lee
    Pharmaceuticals.2023; 16(7): 978.     CrossRef
  • Chenodeoxycholic Acid Improves Embryo Implantation and Metabolic Health through Modulating Gut Microbiota–Host Metabolites Interaction during Early Pregnancy
    Meixia Chen, Ying Zhao, Haifeng Ji, Lu Li, Hui Liu, Sixin Wang, Dongyan Zhang, Jingdong Yin, Jing Wang, Xin Zhang
    Antioxidants.2023; 13(1): 8.     CrossRef
  • Temporal profile of cerebrospinal fluid galactin-3 and associated cytokine responses after severe traumatic brain injury in patients: a retrospective study
    Melisa Cetin, Ping Yip, Zhou-Hao Liu
    Future Healthcare Journal.2023; 10: S18.     CrossRef
  • Temporal profile of cerebrospinal fluid galactin-3 and associated cytokine responses after severe traumatic brain injury in patients: a retrospective study
    Melisa Cetin, Ping Yip, Wing Sze Leung, Zhou-Hao Liu
    Clinical Medicine.2023; 23(6): 81.     CrossRef
  • Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy
    Hongqun Liu, Henry H. Nguyen, Ki Tae Yoon, Samuel S. Lee
    Frontiers in Network Physiology.2022;[Epub]     CrossRef
  • Collagen-binding fibroblast growth factor ameliorates liver fibrosis in murine bile duct ligation injury
    Qiangqiang Shi, Susu Wei, Zhi Chao Li, Jing Xu, Yaxin Li, Chuanlong Guo, Xianggen Wu, Chunying Shi, Guohu Di
    Journal of Biomaterials Applications.2022; 37(5): 918.     CrossRef
  • 9,017 View
  • 141 Download
  • 9 Web of Science
  • Crossref